ProQR Therapeutics N.V. Stock News

Shares of ProQR Therapeutics (NASDAQ:PRQR) have been given an average rating of Buy by the nine research firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages []

Shares of ProQR Therapeutics (NASDAQ:PRQR) crossed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $7.86 and traded as low as $7.41. ProQR Therapeutics shares last traded at $7.50, with a volume of 301,156 shares. A number of brokerages have issued reports on PRQR. []

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tr

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the Company), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today hosted a virtual Analyst Event. Management provided an in-depth review of the Companys clinical-stage programs and RNA editing technology platforms.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Roche's Spark Subsidiary Reports Positive Phase 1/2 Data For Hemophilia Gene Therapy Candidate Roche H

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at multiple conferences. Among the

LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of tran

LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative R

Today, we revisit ProQR Therapeutics, an intriguing developmental concern for the first time since early this year.

Investors need to pay close attention to ProQR (PRQR) stock based on the movements in the options market lately.

A new collaboration deal with Eli Lilly could be worth up to $1.3 billion.

The stock price of ProQR Therapeutics N.V. (Nasdaq: PRQR) increased over 13% pre-market this morning.

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through the creation of transformative

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) --  ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), today announced a global licensing and research collaboration with Eli Lill

LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 06, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA ther